CLOs on the Move

British Biotech plc

www.britbio.co.uk

 
British Biotech plc is a Annapolis, MD-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Stolt-Nielsen Transportation Group

Stolt-Nielsen Transportation Group is one of the largest and most sophisticated parcel tanker operators in the world. Through its modern fleet, global network of terminals, storage facilities and tank containers, SNTG offers a powerful range of

Basic Materials Corp

Basic Materials Corp is a Waterloo, IA-based company in the Business Services sector.

Energy Management Corporation

Your leading electric motors, variable frequency drives, and backup generators distribution and service company since 1974

Parker Technical

Parker Technical is a Seattle, WA-based company in the Business Services sector.

Apellis Pharmaceuticals

Apellis Pharmaceuticals is a global biopharmaceutical company based in Waltham, Massachusetts. The company is focused on developing innovative therapies that target the complement system, a crucial part of the immune system. Apellis aims to create life-changing treatments for various debilitating diseases through its commitment to scientific research and patient care. The company has a diverse pipeline of products, including EMPAVELI, which is approved for treating paroxysmal nocturnal hemoglobinuria and is being investigated for other conditions. SYFOVRE is in development for geographic atrophy, along with a combination therapy involving APL-APL-3007. Apellis is also exploring RNA therapies and gene-edited treatments for multiple therapeutic areas. With a global presence in countries such as the US, Canada, and several European nations, Apellis serves patients and healthcare providers affected by diseases related to the complement system. The company reported approximately $709 million in U.S. net product revenues for the full year 2024, reflecting its strong market position and commitment to advancing its therapeutic offerings.